Aptamers Selected to Postoperative Lung Adenocarcinoma Detect Circulating Tumor Cells in Human Blood

Molecular Therapy

Volumn 23, Issue 9, 2015, Pages 1486-1496

  Zamay, Galina S ^a,b   Kolovskaya, Olga S ^a,b   Zamay, Tatiana N ^a,c   Glazyrin, Yury E ^a   Krat, Alexey V ^d   Zubkova, Olga ^a   Spivak, Ekaterina ^a,c   Wehbe, Mohammed ^e   Gargaun, Ana ^e   Muharemagic, Darija ^e   Komarova, Mariia ^a   Grigorieva, Valentina ^a,c   Savchenko, Andrey ^a,c   Modestov, Andrey A ^d   Berezovski, Maxim V ^e   Zamay, Anna S ^a,b  

^a KRASNOYARSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^b KRASNOYARSK SCIENTIFIC CENTER   (Russian Federation)

^c SIBERIAN FEDERAL UNIVERSITY   (Russian Federation)

^d Kryzhanovsky Krasnoyarsk Regional Clinical Cancer Center (KKRCCC)   (Russian Federation)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; CLUSTERIN; DEFENSIN; HISTONE H2B; LIPOCORTIN 2; LIPOCORTIN 5; TUMOR MARKER; VIMENTIN; CARRIER PROTEIN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; CANCER GRADING; CELL LINE; CHEMISTRY; GENETICS; LUNG NEOPLASMS; METABOLISM; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; TUMOR EMBOLISM;

ADENOCARCINOMA; APTAMERS, NUCLEOTIDE; BIOMARKERS, TUMOR; CARRIER PROTEINS; CELL LINE; HUMANS; LUNG NEOPLASMS; NEOPLASM GRADING; NEOPLASTIC CELLS, CIRCULATING; POSTOPERATIVE PERIOD; PROTEIN BINDING; SELEX APTAMER TECHNIQUE;

EID: 84940720719     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.108     Document Type: Article

References (35)

1. Siegel, R, Naishadham, D and Jemal, A (2013). Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Spiro, SG and Silvestri, GA (2005). One hundred years of lung cancer. Am J Respir Crit Care Med 172: 523-529.
3. Punnoose, EA, Atwal, S, Liu, W, Raja, R, Fine, BM, Hughes, BG et al. (2012). Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18: 2391-2401.
4. Joosse, SA and Pantel, K (2013). Biologic challenges in the detection of circulating tumor cells. Cancer Res 73: 8-11.
5. Rossi, E, Basso, U, Celadin, R, Zilio, F, Pucciarelli, S, Aieta, M et al. (2010). M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 16: 5233-5243.
6. Krebs, MG, Metcalf, RL, Carter, L, Brady, G, Blackhall, FH and Dive, C (2014). Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 11: 129-144.
7. Mikolajczyk, SD, Millar, LS, Tsinberg, P, Coutts, SM, Zomorrodi, M, Pham, T et al. (2011). Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol 2011: 252361.
8. Shen, Q, Xu, L, Zhao, L, Wu, D, Fan, Y, Zhou, Y et al. (2013). Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates. Adv Mater 25: 2368-2373.
9. Liu, G, Mao, X, Phillips, JA, Xu, H, Tan, W and Zeng, L (2009). Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells. Anal Chem 81: 10013-10018.
10. Medley, CD, Bamrungsap, S, Tan, W and Smith, JE (2011). Aptamer-conjugated nanoparticles for cancer cell detection. Anal Chem 83: 727-734.
11. Chen, HW, Medley, CD, Sefah, K, Shangguan, D, Tang, Z, Meng, L et al. (2008). Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 3: 991-1001.
12. Ostroff, RM, Bigbee, WL, Franklin, W, Gold, L, Mehan, M, Miller, YE et al. (2010). Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5: e15003.
13. Kunii, T, Ogura, S, Mie, M and Kobatake, E (2011). Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst 136: 1310-1312.
14. Cerchia, L, Esposito, CL, Camorani, S, Rienzo, A, Stasio, L, Insabato, L et al. (2012). Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther 20: 2291-2303.
15. Jiménez, E, Sefah, K, López-Colón, D, Van Simaeys, D, Chen, HW, Tockman, MS et al. (2012). Generation of lung adenocarcinoma DNA aptamers for cancer studies. PLoS One 7: e46222.
16. Esposito, CL, Cerchia, L, Catuogno, S, De Vita, G, Dassie, JP, Santamaria, G et al. (2014). Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. Mol Ther 22: 1151-1163.
17. Zamay, TN, Kolovskaya, OS, Glazyrin, YE, Zamay, GS, Kuznetsova, SA, Spivak, EA et al. (2014). DNA-aptamer targeting vimentin for tumor therapy in vivo. Nucleic Acid Ther 24: 160-170.
18. Berezovski, MV, Lechmann, M, Musheev, MU, Mak, TW and Krylov, SN (2008). Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 130: 9137-9143.
19. Fan, C, Lin, X and Wang, E (2012). Clinicopathological significance of cathepsin D expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: An immunohistochemistry study. Tumour Biol 33: 1045-1052.
20. Abbott, DE, Margaryan, NV, Jeruss, JS, Khan, S, Kaklamani, V, Winchester, DJ et al. (2010). Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther 9: 23-30.
21. Kirana, C, Shi, H, Laing, E, Hood, K, Miller, R, Bethwaite, P et al. (2012). Cathepsin D Expression in Colorectal Cancer: From Proteomic Discovery through Validation Using Western Blotting, Immunohistochemistry, and Tissue Microarrays. Int J Proteomics 2012: 245819.
22. Taenzer, A, Alix-Panabières, C, Wikman, H and Pantel, K (2012). Circulating tumorderived biomarkers in lung cancer. J Thorac Dis 4: 448-449.
23. Zhao, Z, Xu, L, Shi, X, Tan, W, Fang, X and Shangguan, D (2009). Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst 134: 1808-1814.
24. Deng, S, Wang, J, Hou, L, Li, J, Chen, G, Jing, B et al. (2013). Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett 5: 107-112.
25. Paterlini-Brechot, P and Benali, NL (2007). Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253: 180-204.
26. Lou, X, Xiao, T, Zhao, K, Wang, H, Zheng, H, Lin, D et al. (2007). Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J Proteome Res 6: 1083-1092.
27. Havel, LS, Kline, ER, Salgueiro, AM and Marcus, AI (2015). Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene 34: 1979-1990.
28. Kidd, ME, Shumaker, DK and Ridge, KM (2014). The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol 50: 1-6.
29. Richardson, F, Young, GD, Sennello, R, Wolf, J, Argast, GM, Mercado, P et al. (2012). The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second-or third-line therapy. Anticancer Res 32: 537-552.
30. Corsten, MF, Hofstra, L, Narula, J and Reutelingsperger, CP (2006). Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res 66: 1255-1260.
31. Cole, AJ, Clifton-Bligh, R and Marsh, DJ (2015). Histone H2B monoubiquitination: roles to play in human malignancy. Endocr Relat Cancer 22: T19-T33.
32. Espinosa, JM (2008). Histone H2B ubiquitination: The cancer connection. Genes Dev 22: 2743-2749.
33. Holterman, DA, Diaz, JI, Blackmore, PF, Davis, JW, Schellhammer, PF, Corica, A et al. (2006). Overexpression of alpha-defensin is associated with bladder cancer invasiveness. Urol Oncol 24: 97-108.
34. Cai, L, Dong, HY and Sui, GJ (2005). Effects of navelbine and docetaxel on gene expression in lung cancer cell strains. Acta Pharmacol Sin 26: 1017-1024.
35. Chou, TY, Chen, WC, Lee, AC, Hung, SM, Shih, NY and Chen, MY (2009). Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymalto-epithelial transition through modulating the ERK/Slug pathway. Cell Signal 21: 704-711.